[1]刘 宏,张春华,阳 宏,等.肝细胞肝癌患者血清LG2m和hPG80表达水平及临床价值研究[J].现代检验医学杂志,2024,39(01):83-89.[doi:10.3969/j.issn.1671-7414.2024.01.015]
　LIU Hong,ZHANG Chunhua,YANG Hong,et al.Study on the Expression Levels and Clinical Value of Serum LG2m and hPG80 in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2024,39(01):83-89.[doi:10.3969/j.issn.1671-7414.2024.01.015]
点击复制

肝细胞肝癌患者血清LG2m和hPG80表达水平及临床价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年01期
页码:
83-89
栏目:
论著
出版日期:
2024-01-15

文章信息/Info

Title:
Study on the Expression Levels and Clinical Value of Serum LG2m and hPG80 in Patients with Hepatocellular Carcinoma
文章编号:
1671-7414（2024）01-083-07
作者:
刘 宏;  张春华;  阳 宏;  王万琴
（成都市双流区第一人民医院/ 四川大学华西空港医院消化内科，成都 610200）
Author(s):
LIU Hong;  ZHANG Chunhua;  YANG Hong;  WANG Wanqin
（Department of Gastroenterology，the First People’s Hospital of Shuangliu District/West China Airport Hospital of Sichuan University, Chengdu 610200, China）
关键词:
肝细胞肝癌; 层黏连蛋白γ2 单体; 人循环前胃泌素
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.01.015
文献标志码:
A
摘要:
目的　研究肝细胞肝癌(hepatocellular carcinoma，HCC) 患者血清层黏连蛋白γ2 单体(laminin gamma 2monomer，LG2m)、人循环前胃泌素（human circulating gastrin，hPG80）表达水平及临床价值。方法　选取2016 年1 月～ 2018年1 月成都市双流区第一人民医院收治的128 例HCC 患者为HCC 组，以同期诊治的70 例肝脏良性病变患者为良性病变组，以同期体检的70 例健康人为对照组。应用酶联免疫吸附试验检测血清LG2m 和hPG80 水平。受试者工作特征（ROC）曲线分析血清LG2m 和hPG80 对HCC 患者预后的评估价值。Kaplan-Meier 生存分析比较不同血清LG2m 和hPG80 水平HCC 患者生存预后差异。COX 回归分析影响HCC 患者预后的因素。结果　HCC 组血清LG2m（28.14±3.10ng/L），hPG80（84.83±11.39 ng/L）水平高于良性病变组（9.18±1.74 ng/L，25.10±4.11 ng/L）和对照组（8.24±1.65ng/L，23.15±3.26 ng/L），差异具有统计学意义(t=68.240 ～ 76.635，均P<0.05)。TNM 分期Ⅲ期、低分化程度、血清AFP>400μg/L 患者血清LG2m，hPG80 水平高于TNM 分期I ～Ⅱ期、高中分化程度、AFP ≤ 400μg/L 患者，差异具有统计学意义(t=3.216 ～ 13.552，均P<0.05)。血清LG2m，hPG80 联合检测对HCC 患者预后评估的曲线下面积(95%CI)为0.934(0.889 ～ 0.961)，大于单项指标检测0.813（0.774 ～ 0.849），0.896(0.840 ～ 0.937)。血清LG2m 高表达和低表达HCC 患者的五年总体生存率分别为33.33%（21/63），67.69%（44/65）。与血清LG2m 低表达HCC 患者相比，血清LG2m 高表达HCC 患者五年累积生存率更低(Log-Rankχ2=19.522，P ＜ 0.05)。血清hPG80 高表达和低表达HCC 患者的五年总体生存率分别为35.48%（22/62），65.15%（43/66）。与血清hPG80 低表达HCC 患者相比，血清hPG80高表达HCC 患者五年累积生存率更低(Log-Rankχ2=12.546，P ＜ 0.05)。TNM 分期Ⅲ期（OR=1.487，P ＜ 0.05）、低分化程度（OR=1.611，P ＜ 0.05）、血清AFP ≥ 400μg/L（OR=1.416，P ＜ 0.05）、血清LG2m（OR=1.838，P ＜ 0.05）高表达、hPG80（OR=1.735，P ＜ 0.05）高表达是HCC 患者不良预后的独立危险因素。结论　HCC 患者血清LG2m 和hPG80 水平升高，两者与TNM 分期、肿瘤分化程度及血清AFP 水平有关，是评估HCC 患者生存预后的血清标志物。
Abstract:
Objective　To study the serum laminin γ 2 monomer (LG2m)，human circulating Gastrin (hPG80) in patients with hepatocellular carcinoma (HCC) and their clinical value. Methods　128 HCC patients admitted to the First People’s Hospital of Shuangliu District from January 2016 to January 2018 were selected as the HCC group, 70 patients with benign liver lesions diagnosed and treated at the same time were selected as the benign lesion group, and 70 healthy individuals who underwent physical examinations during the same time were selected as the control group. Use enzyme-linked immunosorbent assay to detect serum LG2m and hPG80 levels. The evaluation value of serum LG2m and hPG80 in predicting the prognosis of HCC patients were analyzed by receiver operating characteristic curve. Kaplan-Meier survival analysis was used to compare the survival prognosis of HCC patients with different serum LG2m and hPG80 levels. COX regression analysis was used to analyze the prognostic factors of HCC patients. Results　The levels of serum LG2m（28.14±3.10 ng/L）, hPG80（84.83±11.39 ng/L） in the HCC group were higher than those in the benign lesion group （9.18±1.74 ng/L，25.10±4.11 ng/L）and the control group（8.24±1.65 ng/L，23.15±3.26 ng/L）, and the differences were statistically significant(t=68.240 ～ 76.635, all P<0.05). The levels of serum LG2m and hPG80 in patients with TNM stage III, low differentiation degree, serum AFP>400 μg/L were higher than those in TNM stage I to II, high differentiation, AFP≤ 400 μg/L, the differences were statistically significant (t=3.216 ～ 13.552，all P<0.05). The area under the curve (95% CI) of the combined evaluation of serum LG2m and hPG80 for the prognosis of HCC patients was 0.934 (0.889 ～ 0.961), which was greater than the single indicator of 0.813 (0.774 ～ 0.849) and 0.896 (0.840 ～ 0.937).The overall 5-year survival rates of HCC patients with high and low serum LG2m expression were 33.33% (21/63) and 67.69% (44/65), respectively. Compared with HCC patients with low expression of serum LG2m, HCC patients with high expression of serum LG2m had a lower 5-year cumulative survival rate (Log-Rankχ2=19.522, P ＜ 0.05).The overall 5-year survival rates of HCC patients with high and low serum hPG80 expression were 35.48% (22/62) and 65.15% (43/66), respectively. Compared with HCC patients with low serum hPG80 expression, HCC patients with high serum hPG80 expression had a lower 5-year cumulative survival rate (Log-Rankχ2=12.546, P ＜ 0.05). TNM stage III (OR=1.487, P ＜ 0.05), low differentiation degree (OR=1.611，P ＜ 0.05), serum AFP ≥ 400μg/L (OR=1.416, P ＜ 0.05), high expression of serum LG2m (OR=1.838, P ＜ 0.05), and high expression of hPG80 (OR=1.735，P ＜ 0.05) were independent risk factors for poor prognosis in HCC patients. Conclusion　The serum levels of LG2m and hPG80 in HCC patients increase, which are related to TNM staging, tumor differentiation, and serum AFP levels. They are serum biomarkers for evaluating the survival and prognosis of HCC patients.

参考文献/References:

[1] KONYN P, AHMED A, KIM D. Current epidemiology in hepatocellular carcinoma[J]. Expert Review of Gastroenterology & Hepatology, 2021, 15(11): 1295-1307.
[2] 张鑫浩, 张涛元, 李俏, 等. 基于GEO 芯片数据的肝癌关键生物标志物的筛选与鉴定及生物信息学分析[J]. 现代检验医学杂志, 2020, 35(4): 26-31． ZHANG Xinhao, ZHANG Taoyuan, LI Qiao, et al. Screening, identification and bioinformatics analysis of key biomarkers for hepatocellular carcinoma based on GEO chip data [J]. Journal of Modern Laboratory Medicine, 2020, 35(4): 26-31.
[3] KARASHIMA T, UMEMOTO S, KISHIDA T, et al. Clinical evaluation of urine laminin-γ2 monomer as a potent biomarker for non-muscle invasive bladder cancer[J]. Cancer Medicine, 2023, 12(3): 2453-2462.
[4] DAISUKE H, KATO H, FUKUMURA K, et al. Novel LAMC2 fusion protein has tumor-promoting properties in ovarian carcinoma[J]. Cancer Science, 2021, 112(12): 4957-4967.
[5] CHAUHAN A, PRIEUR A, KOLESAR J, et al. HPG80(circulating progastrin),a novel blood-based biomarker for detection of poorly differentiated neuroendocrine carcinoma and well differentiated neuroendocrine tumors[J]. Cancers, 2022, 14(4): 235-243.
[6] KOHLI M, TAN W, VIRE B, et al. Prognostic value of plasma hPG80 (circulating progastrin) in metastatic renal cell carcinoma [J]. Cancers (Basel), 2021, 13(3): 375.
[7] 杨帆, 曹毛毛, 李贺, 等.1990-2019 年中国人群肝癌流行病学趋势分析及预测[J]. 中华消化外科杂志, 2022, 21(1): 106-113. YANG Fan, CAO Maomao, LI He, et al. Analysis and prediction of the epidemiological trend of liver cancer in the Chinese population from 1990 to 2019 [J].Chinese Journal of Digestive Surgery, 2022, 21(1): 106-113.
[8] 杨鑫, 贾户亮, 钦伦秀. 肝癌术后复发的分子机制及其预测研究进展[J]. 中国实用外科杂志, 2019, 39(10): 1030-1035． YANG Xin, JIA Huliang, QIN Lunxiu. Progress in the molecular mechanism and the prediction of postoperative recurrence of hepatocellular carcinoma[J]. Chinese Journal of Practical Surgery, 2019, 39(10): 1030-1035.
[9] YASUDA H, NAKAGAWA M, KIYOKAWA H, et al. Unique biological activity and potential role of monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma: a review [J]. International Journal of Molecular Sciences, 2019, 20(1): 226.
[10] GUO Danfeng, ZHANG Xiaodan, CUI Honglei, et al. ACADL functions as a tumor suppressor in hepatocellular carcinoma metastasis by inhibiting matrix metalloproteinase 14 [J]. Front Oncol, 2022, 12: 821484.
[11] BUDUNELI E, VARDAR-?ENG?L S, BUDUNELI N, et al. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 γ2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate[J]. Journal of Periodontology, 2007, 78(1): 127-134.
[12] KIRTONIA A, PANDEY A K, RAMACHANDRAN B, et al. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade[J].Cellular and Molecular Life Sciences, 2022, 79(7): 362.
[13] SCIALPI R, ARR? V, GIANNELLI G, et al. Laminin-332 γ2 monomeric chain promotes adhesion and migration of hepatocellular carcinoma cells[J].Cancers (Basel), 2023, 15(2): 373.
[14] OKADA Y, TAKAHASHI N, TAKAYAMA T, et al. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATPbinding cassette transporters in pancreatic ductal adenocarcinoma[J]. Carcinogenesis, 2021, 42(4): 546-556.
[15] CAPPELLINI M, FLACELIERE M, SAYWELL V, et al. A novel method to detect hPG80 (human circulating progastrin) in the blood[J]. Anal Methods, 2021, 13(38): 4468-4477.
[16] PRIEUR A, HARPER A, KHAN M, et al. Plasma hPG80(circulating progastrin) as a novel prognostic biomarker for early-stage breast cancer in a breast cancer cohort[J]. BMC Cancer, 2023, 23(1): 305-311.
[17] DUPUY M, ILTACHE S, RIVIERE B, et al. Plasma hPG80 (circulating progastrin) as a novel prognostic biomarker for hepatocellular carcinoma. [J].Cancers (Basel), 2022, 14(2): 478-483.
[18] TANG E, WANG Yongfeng, LIU Tiemei, et al. Gastrin promotes angiogenesis by activating HIF-1α/β-catenin/VEGF signaling in gastric cancer[J]. Gene, 2019, 704: 42-48.
[19] HE Shuai, TANG Shilei. WNT/β-catenin signaling in the development of liver cancers[J]. Biomedecine & Pharmacotherapie, 2020, 132: 110851.
[20] TANAKA H, KAWAGUCHI M, SHODA S, et al. Nuclear accumulation of β-catenin in cancer stem cell radioresistance and stemness in human colon cancer[J].Anticancer Research, 2019, 39(12): 6575-6583.
[21] YOU B, MERCIER F, ASSENAT E, et al. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients [J]. EBio Medicine, 2020, 51: 102574.
[22] 李长贤, 张慧, 吴晓峰, 等. 不同中国肝癌分期肝癌根治性切除术后的临床效果及预后因素分析[J]. 中华外科杂志, 2021, 59(2): 134-143． LI Changxian, ZHANG Hui, WU Xiaofeng, et al. Clinical efficacy and prognostic factors analysis following curative hepatectomy for hepatocellular carcinoma patients with different China liver cancer staging [J]. Chinese Journal of Surgery, 2021, 59(2): 134-143.

备注/Memo

备注/Memo:
基金项目：四川省医学卫生健康科研课题（19PJ065）：肝细胞肝癌（HCC）患者血清LG2m，hPG80 的水平及临床意义。
作者简介：刘宏（1984-），男，硕士研究生，主治医师，主要从事消化肿瘤工作及研究，E-mail：liuhong201407@126.com。
更新日期/Last Update: 2024-01-15